	Application No.	Applicant(s)
	10/074,596	ROSENBLUM ET AL.
Notice of Allowability	Examiner	Art Unit
	Karen Cochrane Carlson, Ph.D.	1653
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>November 28, 2006</u> .		
2. The allowed claim(s) is/are <u>1-11,13-15,18,21-27,30-36,50-57 and 59-61</u> .		
 3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the: 1. Certified copies of the priority documents have been received. 		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) 🔲 hereto or 2) 🔲 to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s) 1. Notice of References Cited (PTO-892)	5. ☐ Notice of Informal P	atent Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ☐ Interview Summary Paper No./Mail Dat	
3. Information Disclosure Statements (PTO-1449 or PTO/SB/0		
Paper No./Mail Date 11/2005 4. Examiner's Comment Regarding Requirement for Deposit	8. 🛛 Examiner's Stateme	ent of Reasons for Allowance
of Biological Material	9.	
·		

Art Unit: 1653

This Notice of Allowability is in response to the paper filed November 28, 2006 and to the agreement to the Examiner's Amendments presented below.

Claims 12, 19, 37-49, 58, and 62-98 have been canceled. Claims 1-11, 13-18, 20-36, 50-57, and 59-61 are currently pending.

An **Examiner's Amendment** to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with David L. Parker on January 19, 2006.

Examiner's Amendments to the Claims:

In Claim 7, please replace "claim 1" with — claim 6 —.

In Claim 8, please replace "claim 1" with --- claim 7 ---.

Please cancel Claim 16.

Please cancel Claim 17

20. (Currently Amended) A modified <u>gelonin</u> enzyme produced by the process comprising:

- a) identifying one or more antigenic regions in the gelonin enzyme using an antibody;
- b) removing one or more antigenic regions from the <u>gelonin</u> enzyme to form a modified <u>gelonin</u> enzyme; and
- e) determining that the modified <u>gelonin</u> enzyme has enzymatic activity;

 further wherein either i) the enzyme is gelonin toxin; or ii) a second polypeptide is conjugated or fused to the modified enzyme.

Please cancel Claims 28 and 29.

Application/Control Number: 10/074,596 Page 3

Art Unit: 1653

The following is an **Examiner's Statement of Reasons for Allowance**: The prior art of record

does not teach or suggest gelonin comprising amino acids 110-210 of SEQ ID NO: 1 with at least

10 amino acids absent and at least 5 amino acids replaced, or modified gelonin comprising

amino acids 110-210 of SEQ ID NO: 1 conjugated or fused to an antibody against a tumor

antigen, or a functional modified gelonin having one or more antigenic regions removed.

Therefore, the claims are allowable over the art of record.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Summary:

Claims 12, 16, 17, 19, 28, 29, 37-49, 58, and 62-98 have been canceled.

Claims 1-11, 13-15, 18, 21-27, 30-36, 50-57, and 59-61 are allowable.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen Cochrane Carlson, Ph.D. whose telephone number is 571-272-0946. The examiner can normally be reached on 7:00 AM - 4:00 PM, off alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Jon Weber can be reached on 571-272-0925. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

KAREN COCHRANE CARLSON, PH.D PRIMARY EXAMINER